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Objective: This study explores variations in outcomes of care for two types of patient
personas—an older frail person recovering from a hip fracture and a multimorbid older
patient with congestive heart failure (CHF) and diabetes.
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Data Sources: We used individual-level patient data from 11 health systems.
Study Design: We compared inpatient mortality, mortality, and readmission rates at
30, 90, and 365 days. For the hip fracture persona, we also calculated time to surgery.
Outcomes were standardized by age and sex.
Data Collection/Extraction Methods: Data was compiled by the International
Collaborative on Costs, Outcomes and Needs in Care across 11 countries for the
years 2016–2017 (or nearest): Australia, Canada, England, France, Germany, the
Netherlands, New Zealand, Spain, Sweden, Switzerland, and the United States.
Principal Findings: The hip sample across ranged from 1859 patients in Aragon, Spain, to
42,849 in France. Mean age ranged from 81.2 in Switzerland to 84.7 in Australia, and the
majority of hip patients across countries were female. The congestive heart failure (CHF)
sample ranged from 742 patients in England to 21,803 in the United States. Mean age
ranged from 77.2 in the United States to 80.3 in Sweden, and the majority of CHF patients
were males. Average in-hospital mortality across countries was 4.1%. for the hip persona
and 6.3% for theCHF persona. At the yearmark, themeanmortality across all countrieswas
25.3% for the hip persona and 32.7% for CHF persona. Across both patient types, England
reported the highestmortality at 1 year followedby theUnited States. Readmission rates for
all periods were higher for the CHF persona than the hip persona. At 30 days, the average
readmission rate for the hip personawas 13.8% and27.6% for theCHFpersona.
Conclusion: Across 11 countries, there are meaningful differences in health system
outcomes for two types of patients.
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What is known on this topic
• Patient outcomes such as mortality and readmissions are commonly used as measures of per-
formance of heatlh systems.
• There are few sources of comparable mortality rates at different time intervals for high-need,
high-cost populations across countries.
• There are limited international comparisons of hospital readmission rates across countries.
What this study adds
• There is large variability in mortality rates at all time intervals for an older person with frailty
and for an older multimorbid person across 11 high-income countries.
• England and the United States have the highest mortality at 1 year for an older person with a
hip fracture and for an older multimorbid person with heart failure and diabetes.
• Readmissions across countries are variable and may be related to mortality rates.
1 | INTRODUCTION
A fundamental goal of all health systems is improving the health of
their populations through high-quality care.1,2 International compari-
sons of this objective provide policy makers with the opportunity to
assess their health system's relative performance and, importantly,
have tremendous power to motivate action.2 However, measuring
these outcomes across countries involves distinct challenges, due to
the cross-national variation present in the factors that influence them,
such as patient characteristics, health system structures, and the orga-
nizations involved in health care delivery.3,4
Current sources of comparable health outcomes data across
countries are limited, and even more so if one wants to explore out-
comes that measure the contribution of the health system to health
outcomes.2,3 While there are a few databases that regularly collect
and report population health outcomes, such as life expectancies and
avoidable mortality, these data are aggregated across all populations
and conditions. Therefore, it is challenging for policy makers to clearly
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tease out how much of this variation is due to differences in service
delivery. For specific conditions, such as cancer, acute myocardial
infarction (AMI), and stroke, some international data are available,
such as 30-day case-fatality rates from the Organization for Economic
Cooperation and Development (OECD) or cancer survival rates from
Eurocare. Other measures of health care quality, such as readmission
rates or mortality figures for specific conditions, are only available
from comparative European projects,5,6 giving us only rare glimpses
into comparative assessments of health care. As a result, we have
limited information on the extent to which differences in health care
system delivery influences quality for short- and long-term outcomes,
particularly for high-need high-cost (HNHC) patients. For policy
makers to be able to take action on comparative results, they need
more information on cross-national outcomes for specific patient
types to be able to robustly compare like with like.
In an attempt to address this gap, the International Collaborative on
Costs, Outcomes and Needs in Care (ICCONIC) explore cross-national
variations in outcomes of care for two types of HNHC patients—an
older frail person, identified as an older adult (older than aged 65 years)
recovering from a hip fracture and a multimorbid older patient, identified
as an older adult (aged 65–90 years) with a diagnosis of CHF and
diabetes—across 11 countries: Australia, Canada, England, France, Ger-
many, the Netherlands, New Zealand, Spain, Sweden, Switzerland, and
the United States. Using an approach similar to tracer conditions,5–10
which builds on previous international work, we define and follow these
two specific types of HNHC patients over the course of a year to exam-
ine variation in short- and long-term outcomes, across their pathway of
care. Our study focuses on the following three questions: (1) How do
health outcomes, such as mortality and readmission rates, vary for two
distinct HNHC populations across countries over the course of a year?
(2) How does process quality, such as time to surgery for hip fracture
vary across countries? (3) and finally, To what extent are differences in
patient comorbidity and length of stay (LOS) across countries correlated
with mortality for these HNHC personas?
2 | DATA AND METHODS
2.1 | Data
The ICCONIC research collaborative collected linked patient-level data
from 2016 to 2017 (or the closest year) from multiple care settings—
spanning primary care, specialty services, acute hospital care, and post-
acute care—across 11 countries, namely, Australia, Canada, England,
France, Germany, the Netherlands, New Zealand, Spain, Sweden, Swit-
zerland, and the United States. Each country collected data on patient
characteristics, comorbidities, utilization, spending, and outcomes for
two prespecified patient cohorts that reflect two different phenotypes
of HNHC patients, as defined by the National Academy of Medicine
HN/HC Framework.11 We identified two specific patient populations
who would belong to each of these two categories as follows: an older
frail person, identified as an individual aged older than 65 years with a
hospital admission for hip fracture (the hip fracture persona) and a
complex, multimorbid patient, identified as an individual aged 65–90
admitted to hospital with a primary diagnosis of congestive heart failure
(CHF) and diabetes as a comorbidity (the CHF with diabetes persona).
For a detailed overview of the methodology employed to collect the
data, see methodology paper from Figueroa et al.12
Most countries used secondary/administrative data sets as the
main source of information to estimate expenditure profiles. These
data sets are large, linked datasets, which are coded and available in
an electronic format. Specific details of each dataset used can be
found in Table S1. The representativeness of the population for each
dataset is found in Table S2. Data in three countries—New Zealand,
Sweden, and Switzerland—covered their entire population. Data in
three other countries were regional samples—Australia (NSW),
Canada (Ontario), and Spain (Aragon region). Data in the remaining
five countries were large, regionally diverse samples, including in
England, France, Germany, the Netherlands, and the United States.
The degree to the proportion of patients covered in each dataset
varied across countries, from 3% in Spain (Aragon) to 100% in
New Zealand, Sweden, and Switzerland.
Identification of both personas required at least 2 years of patient-
level data. Across most countries, we used 2 years between 2015 and
2017, except in Australia (used 2012–2016) and England (2014–2016),
which had smaller samples and so pooled more years of data
(See Table S2).The first year of data was used to identify all relevant
patients through an inpatient admission, either a hip fracture or a heart
failure exacerbation. We then tracked patients for different time inter-
vals into the second year to measure service use and outcomes. For
almost all countries (except Spain and the Netherlands), we used Inter-
national Classification of Diseases, 10th revision (ICD-10) codes, as
defined by the World Health Organization. For the hip fracture per-
sona, the codes included S72.0, S72.1, and S72.2, which represent frac-
tures of the upper femur. In Spain, ICD-9-CM codes were used for
relevant diagnosis and a customized diagnostic codes were derived
with input of clinical experts in the Netherlands, given that ICD codes
were not available in their insurer data. Within this group, we then
focused on the patients who received one of three procedures as fol-
lows: total hip replacement, partial hip replacement, or osteosynthesis—
which include placement of a screw, plate, pin, or internal fixation. Each
country used a clinical expert to identify the relevant procedure codes.
For the heart failure persona, we identified all patients hospital-
ized with a primary diagnosis of CHF (ICD-10 code I50.x) or relevant
codes in Spain (using ICD-9 codes) and in the Netherlands. Given the
lack of comprehensive longitudinal data across most countries, we
were unable to know if the hospitalization was the first hospitalization
related to heart failure or not. We then identified the subset of
patients who at time of the first admission also had a diagnosis of
diabetes, including ICD-10 codes of E11.x, E12.x, E13.x, and E14.x.
2.2 | Key outcomes of interest
The main outcomes of interest in this article are mortality and
readmission rates, including in-hospital mortality and all-cause
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mortality rates or readmission rates at 30, 90, and 365 days. For the
hip fracture persona, we also calculated “time to surgery,” as previ-
ously defined by the OECD (described in further detail below).13
In-hospital mortality is calculated by determining the number of
patients who died within the index hospital admission, at any point in
time, over the total sample population. All-cause mortality is calculated
by determining the number of patients who die within 30, 90, and
365 days from the day of the index hospital admission, including if they
died after being discharged from the hospital admission, over the total
sample population. All-cause readmission rates are calculated by deter-
mining the number of patients who are readmitted to the hospital, within
30, 90, and 365 days from the day of discharge from the index hospital
admission, over the total sample population. All countries, but Switzer-
land, were able to provide estimates of overall mortality and readmission
over the 30-, 90-, and 365-day period. Two countries, France and the
Netherlands, were not able to identify the exact date of death outside of
the hospital in their data. France was only able to identify the quarter of
death and, therefore, does not report 30-day overall mortality and may
have slightly upward-biased estimates for the other mortality estimates,
aside from in-hospital mortality. In the Netherlands, deaths were regis-
tered on the last date of each month. Therefore, an additional time
window of 15 days was used calculate mortality rates. This may have
slightly attenuated mortality estimates, especially for shorter outcome
intervals like in-hospital mortality and 30-day mortality.
For the hip fracture persona, we also examined the “time to sur-
gery” during index hospitalization. In line with the OECD,13 we used
the “same day,” “next day,” “third day” terminologies to classify the
day of procedure, starting from the first day of hospitalization, and
report what percentage out of the total number of patients received a
procedure. If there are multiple types of procedures reported for one
patient, we counted the days to the first procedure that patients
received. Hospital transfers were linked and defined as one episode.
2.3 | Analysis
All outcomes were stratified by sex and specific age groups, allowing for
direct age–sex standardization to the data. This adjusts for differences in
the age and sex structures of the cohort. In total, we collected five groups
per sex, per country for the CHF with diabetes persona (65–69, 70–74,
75–79, 80–84, 85–90 years, and last age category includes 6 years) and
seven groups, per sex, per country for the hip fracture persona (65–69,
70–74, 75–79, 80–84, 85–90, 90–94, and 95 years or older as last group).
As expected, given the specific nature of the pathways we are exploring,
the sample populations differ significantly from the structure of the
general population. For this reason, we used the US sample as the refer-
ence population rather than relying on an external standard.
While we collected comorbidity data for the aggregate groups of
patients, we did not adjust for this, given the variability in coding sys-
tems across countries.12 To illustrate the magnitude of these coding
differences, we used scatterplots to depict the association of 30-day
mortality and number of comorbidities by age–sex groupings, across
countries (seven groups for the hip persona and five groups for the
CHF persona). In addition, we used scatter plots to examine the asso-
ciation between inpatient morality and index LOS. We also examined
the association between 30-day mortality and 30-day readmission
rates, which are competing outcomes.
3 | RESULTS
3.1 | Patient characteristics across countries
For the hip persona, sample sizes ranged from 1859 in Aragon, Spain,
to 42,849 patients in the France (See Table S1). Mean age (standard
deviation [SD]) ranged from 81.2 (6.9) in Switzerland to 84.7 (7.7) in
Australia. The majority of the hip fracture samples across countries
were female, ranging from 62.8% in Australia to 76.7% in Spain.
Germany and the United States had the highest mean number of
comorbidities recorded in their datasets relative to other countries.
Sample sizes for the heart failure persona with diabetes ranged
from 742 in England to 21,803 in the United States. Mean age
(SD) ranged from 77.2 (7.0) in the United States to 80.3 (6.8) in
Sweden. Across most countries, except in the United States, there were
more males than females represented in their samples. The United
States and Germany recorded the highest number of comorbidities per
person as compared to other countries. Sweden and Canada recorded
the fewest number of comorbidities for both personas.
3.2 | Mortality rates across countries
Figure 1 shows in-hospital mortality and overall mortality (at 30,
90, and 365 days) for the hip fracture (1a) and heart failure
(1b) personas. We observed considerable variation across countries.
Australia reported the lowest in-hospital mortality (1.5%) for the hip
fracture patient, whereas England reported the highest in-hospital
mortality at 11.5%. The average in-hospital mortality across the group
of countries was 4.1%. For CHF with diabetes, the average in-hospital
mortality across countries was 6.3%, with the United States reporting
lowest in-hospital mortality at 3.0% and England the highest at 14.7%.
Most countries were able to provide estimates for 30-day overall
mortality for both personas, with the exception of France and
Switzerland. For hip fracture, the average mortality across the nine
countries able to provide data was 7.1%, and for CHF with diabetes, it
was slightly higher at 9.6%. For the hip fracture persona, Australia
reported the lowest 30-day mortality rate at 5.5%, while Spain
reported the lowest rate for the CHF with diabetes persona at 8.1%.
Across both personas, England reported the highest (9.8% for hip frac-
ture and 15.9% for CHF with diabetes). Notably, the English rate of
30-day overall mortality for hip fracture was lower in-hospital mortal-
ity (measured at any time).
All countries, except for Switzerland, were able to provide esti-
mates of 90- and 365-day mortality. On average, 90-day mortality for
the hip fracture persona and CHF with diabetes persona was 14.0%
and 16.9%, respectively, across all countries. England reported the
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highest mortality for both types of patients, while Australia reported
the lowest for both patients. Finally, at the year mark, the mean mor-
tality across all countries was 25.3% for the hip fracture persona and
32.7% for CHF with diabetes persona. England again reported the
highest mortality for both personas, at 31.3% for hip fracture and
43.2% for CHF with diabetes. The US reported the second highest
mortality rates (hip fracture at 26.7%; CHF with diabetes at 37.6%).
Canada, Australia, and France had the lowest 365-day mortality for
hip fracture at 22.9%, 21.5%, and 20.2%, respectively. France, Spain,
and Australia had the lowest 365-day mortality for CHF with diabetes
at 29.2%, 28.5%, and 22.5%, respectively.
3.3 | Relationship of mortality rates
with comorbidities
We examined the correlation between mortality rates to mean number
of comorbidities recorded in each country (Figure 2A,B). We observed
that within countries, the average number of comorbidities recorded
for patients of different age groups changes very little, despite mortality
rates showing a clear relationship to the different age categories, where
patients of different age had different mortality.
3.4 | Relationship of in-hospital mortality
with index LOS
We also examined the association of in-hospital mortality with index
inpatient LOS (Figures S1a, S1b). For hip fracture, there is a positive rela-
tionship between the two variables, where longer LOS is associated with
greater inpatient mortality (Pearson's r = 0.72, p = 0.00). While still posi-
tive, there is a weaker association between in-hospital mortality and
index inpatient LOS for the CHF persona (Pearson's r = 0.20, p = 0.11).
3.5 | Readmission rates across countries
Figure 3 shows readmission rates at 30, 90, and 365 days.
Readmission rates for all periods were higher for the CHF with diabe-
tes persona than the hip fracture persona. At 30 days, the average
readmission rate for the hip fracture persona was 13.8% and 27.6%
for the CHF with diabetes persona. At 30 days, Australia had notably
high readmission rates for both personas, while England had the low-
est readmission rates for both personas.
At 90 and 365 days, Australia continued to have the highest
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Australia Canada England France* Germany Netherlands* New Zealand Spain Sweden Switzerland USA
Panel B: Older Person with a Heart Failure Exacerbation & Diabetes
In-hospital 30-days 90-days 1-year
F IGURE 1 Mortality rates across countries. *Not able to identify the exact date of death outside the hospital. France was only able to
identify the quarter of death and, therefore, does not report 30-day overall mortality and may have slightly upward-biased estimates for the other
mortality estimates, aside from in-hospital mortality. In the Netherlands, deaths were registered on the last date of each month. Therefore, an
additional time window of 15 days was used calculate mortality rates
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followed closely by Germany and England at 365 days. For the CHF per-
sona, France and Germany have the highest 1-year rates (75.3% and
70.0%, respectively), and the Netherlands had the lowest rate at 58.8%.
3.6 | Relationship of mortality and readmissions
Finally, we examined the relationship between in-hospital mortality
and 30-day readmissions. We observed a low negative correlation
between them for both personas (hip: Pearson's r = 0.34, p = 0.00,
CHF with diabetes: Pearson's r = 0.13, p = 0.27).
3.7 | Time to surgery for hip fracture
As a measure of quality of care for the hip fracture persona, seven
countries were able to estimate the “time to surgery” (Figure 4).
Across all countries, apart from Spain, over 50% of the sample was
receiving surgery either on the same day or the day following admis-
sion. In Sweden, this was over 85% of the sample. In England and the
United States, the rate of same day or next day surgery exceeded
75%. Spain (Aragon), France, and Canada (Ontario) had the lowest
proportion of patients receiving surgery the same day (9.3%, 12.1%,
and 20.9%, respectively).
4 | DISCUSSION
In this study, we examined key health system outcomes for two
HNHC personas—an older frail adult with a hip fracture and an older
adult with heart failure and diabetes—across 11 high-income coun-
tries. Our approach builds on existing comparative work by exploring
mortality and readmissions for two complex patients for which there
is limited comparable data across countries. We found substantial
(B)
(A) F IGURE 2 (A) Relationship
of comorbidity to 30-day
mortality by 5-year age groups,
hip fracture persona. US = the
United States, CA = Canada,
DE = Germany, ES=Spain,
EN = England, AU = Australia,
NZ = New Zealand, NL = the
Netherlands, CH = Switzerland,
SE = Sweden. (B) Relationship
of comorbidity to 30-day
mortality by 5-year age groups,
heart failure and diabetes
persona. US = the United
States, CA = Canada,
DE = Germany, ES = Spain,
EN = England, AU = Australia,
NZ = New Zealand, NL = the
Netherlands, CH = Switzerland,
SE = Sweden, FR = France
[Color figure can be viewed at
wileyonlinelibrary.com]
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variation in mortality and readmission rates across countries, for both
personas. For the hip fracture persona, we also found differences in
time to surgery from day of admission to hospital. Our results have
important implications for the research community interested in con-
ducting international comparisons as well as national policy makers
interested in understanding their own relative performance in caring
for complex personas. We highlighted some key findings that emerge
from these results.
First, we found variation in mortality rates for both personas
across countries at different time intervals. The notable exception to
this is England, which consistently reports the highest mortality rates
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F IGURE 3 Hospital readmission rates
F IGURE 4 Time to surgery (hip fracture persona)
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30-day mortality rates for hip fracture patients in England (by around
3 percentage points) using data reported by the national hip fracture
registry for the same time period,14 which would still place England
among the countries with the highest mortality rate. Another study
similarly reported lower mortality at 365 days.15 However, both of
these other studies included patients younger than age 65 in their
sample, which may influence their mortality estimates. Furthermore,
the English data used in this study reflect mortality across a range of
years starting from 2014 and may not adequately capture substantial
improvements that have been made in recently. More work should be
carried out on more recent data from a larger national sample to vali-
date these findings. As time to surgery was consistent with other
countries, further research is needed to investigate the role of rehab
and postacute care (delivered by community care and social care,
which are separately organized and funded from the National Health
Service) to understand if this is contributing to the longer inpatient
LOS and higher mortality rates.
Second, after England, we found that the United States ranks the
second highest for 365-year mortality across both personas. This is
notable, as the United States spends comparatively more resources
caring for these patients16,17 and suggests that they are the least effi-
cient system. Unlike England, the United States has slightly lower
average 30-day mortality for both personas. While related analyses
have shown that the United States is spending more both because of
a comparatively higher unit cost and more utilization of postacute
care,16,17 these results suggest that this increased resource use may
not be translating into improved long-term outcomes. Prior work has
similarly found that the United States performs above average when
it comes to measuring performance related to the period immediately
following a hospitalization but then lags behind other countries when
assessing longer, population-level health outcomes.18 The US policy
makers should further investigate how much spending is relatively
allocated to health care services for acute and postacute care services
versus long-term care services, which are currently not covered for
the majority of Medicare patients (such as those who are not also cov-
ered by Medicaid), to better understand the impact this may have on
patient outcomes. Other countries, like the Netherlands and Canada,
two of the countries with the lowest rate of death at 365 days, have
more comprehensive long-term care services support for older
adults.19,20
Third, as has been noted elsewhere, HNHC patients are heteroge-
neous groups, which require different care.21 To date, there has been
limited international work examining more homogenous subtypes to
see if the same countries consistently perform well in treating different
types of patients. We found some variability in relative performance of
countries across the two personas, suggesting that the design of differ-
ent systems may influence the final outcomes of these patients, partic-
ularly where specific policies have been implemented to improve
coordination of care. For example, Spain has relatively low mortality for
the CHF persona, it fares worse relative to other countries on short-
term mortality for hip fracture, possibly related to the longer delays in
receiving surgery after being admitted to the hospital,22,23 which should
be explored further. To further understand the role health system
design and coordination of care influence outcomes, policy makers
should focus on making more data available that follows patients across
care settings. This can be useful to improve the rigor of comparative
analysis, such as this one, as well as national research on this topic.
Fourth, we also explore the relationship between the number of
recorded comorbidities for patients to 30-day mortality. We observed
variability in the average number of comorbidities recorded across
countries, which appear to have more to do with local coding prac-
tices rather than the severity of the patients, as illustrated by the rela-
tive similarity in the number of comorbidities coded by age group
within countries.
Different incentives across countries may influence the coding of
secondary diagnoses and has also been observed elsewhere.24 For
example, in the United States and Germany, insurance systems where
reimbursement is related to patient severity, we see much greater
levels of comorbidity recorded than countries like Canada, Sweden,
and England where providers are reimbursed through global budgets.
As a result, adjusting mortality by the number of comorbidities across
countries may introduce bias.
Fifth, we found substantial variation in readmission rates for both
personas across countries. This is likely influenced by several factors,
including differences in the amount of time patients spend in the hos-
pital and differential use of postacute care rehabilitative services or
long-term care.16,17 Unfortunately, the majority of countries lack com-
prehensive data on long-term care and postacute rehabilitative care,
limiting our ability to explore these relationships further. Of note,
in-hospital mortality was weakly inversely associated with
readmission rate, suggesting a problem of competing risk. In other
words, if more patients are dying in the index hospitalization in one
country, then a comparatively healthier population is being discharged
and serves as the denominator for readmission as has been shown in
other work.25,26 Our work suggests that in order to better interpret
cross-national variation in readmission rate, more comprehensive data
on patient trajectories need to be collected and made available to
researchers.
Finally, we observed important differences in aspects of quality
of care for the hip patients, namely time to surgery, for a subset of
countries. Time to surgery for hip fracture patients has been shown to
influence outcomes, including mortality.27,28 We found considerable
variability across countries in this metric. Sweden and England have
high proportion of patients receiving surgery by the next day possibly
because this target has been recognized in guidelines.29 More vari-
ables detailing important clinical processes are necessary to better
identify actionable areas of improvement across countries and bring
together a more complete picture of variations in care.
This paper makes an important contribution to the literature on
performance comparisons of health system. Other studies and reports
have explored the overall performance of the United States to other
high-income health systems.18 To our knowledge, this is one of the
first articles that provide detailed international data comparing
the health outcomes of two HNHC personas as follows: older patients
with hip fracture and a multimorbid patient with heart failure and dia-
betes. Other comparative studies have explored outcomes for specific
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patient populations, including 30 day and year-long mortality, and
cost-quality, for other common procedures, such as AMI, stroke,
and elective hip replacement.5,6,30–33 In addition, 30-day case fatality
rates for AMI and stroke are also reported by the OECD health care
quality indicators project (https://www.oecd.org/els/health-systems/
hcqi-acute-care.htm). We are not aware of other work that comparing
hospital readmission rates across more than three countries.34
4.1 | Limitations
There are several limitations to this work. First, while we have carried
out our best to ensure data comparability across countries, there are
some differences in national coding practices and the representative-
ness of the data in certain countries that in turn may influence the
results. We noted particular issues with the comparability of the mor-
tality estimates from the French and Dutch data, which may lead to
an underestimation given that they can only record overall deaths at
fixed time periods. In addition, we do not adjust for comorbidities
given the apparent differences in coding practices across countries.
However, given that all patients have similar primary diagnosis and we
adjust for demographics, we did not believe much additional variabil-
ity would be accounted for by this adjustment. Second, we were not
able to adjust for a number of factors that are important predictors of
both short- and long-term mortality, such as baseline severity of the
clinical diagnoses of heart failure or diabetes, nor are we able to
account for differences in socioeconomic status. Third, while we do
report a set of comparative outcomes across countries, we are missing
some of the most important outcomes for these populations, including
mobility outcomes following hip fracture, time spent at home, and
patient-reported outcomes. Further data linkage to all sectors, particu-
larly postacute and long-term care, is needed to make this possible
across countries. Fourth, while this article, and the accompanying body
of work, produces detailed data outlining differences in the utilization,
expenditure, and outcomes of care for these two patient personas, this
work is descriptive, and we cannot make any causal inferences about
which factors in each system impact the observed outcomes. However,
these results can serve to point to areas that merit further investigation.
Finally, due to data restrictions across countries, we were unable to pool
data together to conduct more rigorous analyses of the patient-level
data. In order to advance comparative health systems research in the
future and provide more detailed advice to national policy makers, it is
important that suitable workarounds to this issue are found, while still
protecting the privacy of the data.
5 | CONCLUSIONS
Taken together, these findings suggest that there are meaningful dif-
ferences in health system outcomes across the 11 countries studied,
for two types of HNHC patients as follows: an older frail person with
hip fracture and patients with CHF with diabetes. Further efforts to
link in additional data, particularly on long-term care, would be
beneficial to further understand variability in health outcomes and
health system efficiency.
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